U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847892) titled 'Long-Term Follow-Up Study of Gamgertamig' on Sept. 23.
Brief Summary: This study will follow adults who previously received gamgertamig in another clinical study to evaluate long-term safety and clinical outcomes.
Study Start Date: Oct., 2026
Study Type: OBSERVATIONAL
Condition:
Autoimmune Cytopenias
Intervention:
OTHER: Observational
Prior treatment with gamgertamig in an eligible parent study. No gamgertamig is administered in this follow-up study.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Lakefront Biotherapeutics West LLC
Published by HT Digital Content Services with permission from Health Daily Digest....